FDA Panel Endorses PMAs For Electroshock Therapy Devices
This article was originally published in The Gray Sheet
Executive Summary
A recent vote by an FDA advisory panel favoring more stringent regulation of electroconvulsive therapy devices is not likely to jeopardize future availability of the products on the market, according the panel's chairman.